Search

This study critically reviews the literature on the prevalence and genotypic distribution of Bovine Leukemia Virus (BLV) in Asia, specifically targeting enzootic bovine leukosis, a chronic disease affecting cattle’s life and milk production along with reduced fat yield, that causing economic losses due to increased susceptibility to pathogens. European countries are eradicating BLV but Asia has a high prevalence, particularly in Asian cattle. Enzootic bovine leukosis (EBL) has distinct clinical stages: asymptomatic, persistent lymphocytosis, and lymphosarcoma. It typically occurs in adult animals, with 60% being asymptomatic during the aleukemic stage, 30% developing persistent lymphocytosis, and 5% developing lymphoma. Databases like PubMed and Google Scholar were used to search molecular and prevalence studies from 2000-2024, focusing on Asian countries. Prevalence of bovine leukosis (BL) in Asia varies significantly, with high rates in central and eastern regions. BLV is a global disease, has increased in Asia with highest prevalence in central Asia about 40.0–84.0% (Kazakhstan), 35% in Eastern Asia (Japan), and 58.3% in Southeast Asia (Thailand). BLV genotypes G1, G4, G6, G7, G12, G3, G4, G6, G7, and G10 are prevalent in various regions of Asia, with G1 being most prevalent globally. These genotypes might be spread due to animal trading, and animal domestication, affecting various countries. This review provides the current status of enzootic bovine leukosis in Asia, emphasising the need for a closed trading system to control the disease.

The growing global population has amplified the demand for food, making the international trade of livestock a significant threat to animal and public health due to the increased risk of zoonotic disease transmission through animal movement or the consumption of their products. Biosecurity measures (BSMs) and vaccination are two essential tools that, when effectively implemented, can significantly reduce the spread of diseases from livestock. However, their failure not only escalates the burden of disease but also compromises food security and public health. Weak or poorly enforced BSMs can undermine the efficacy of vaccinations, creating challenges against disease prevention efforts. Conversely, robust BSMs such as nutritional and environmental management, routine monitoring of disease, farm management, and hygiene provide a critical foundation for successful vaccination programs by minimizing disease exposure and ensuring vaccine effectiveness. Inappropriate vaccination administration, inadequate cold chain management, and the frequency of immunosuppressive illnesses are also reported as contributing factors to vaccine failure. This review delves into the interconnected roles of BSMs and vaccination, unveiling the importance of the implementation of biosecurity principles in preventing vaccine failure. It also explores how the integration of biosecurity practices and vaccination strengthens animal health systems, mitigates zoonotic risks, and enhances overall food safety. Future research should concentrate on integrated biosecurity techniques by strengthening on-farm biosecurity protocols, proper handling and administration of vaccines, careful disease surveillance, and awareness programs thereby increasing the resilience of our livestock industry against notable diseases.

CRISPR has become a revolutionary tool for cancer biology and therapy with unprecedented precision for genome editing. Besides cancer, CRISPR is also under research for possible use in the treatment of viral diseases, such as Bovine Viral Diarrhea Virus (BVDV), a serious livestock problem. Through enabling gene modifications to be made to individual genes, CRISPR is used in identifying oncogenic drivers, characterizing tumor suppressor networks, and designing innovative therapeutics. This review focuses on the various uses of CRISPR for cancer studies with special attention to methods like gene knockout, gene activation, and base editing that each has a great potential for correcting oncogenic mutations and restoring tumor suppressor activity. Moreover, CRISPR's capacity to regulate viral replication, as that of BVDV, signifies its dual role in oncology as well as in viral pathogenesis. Interventions based on CRISPR such as chimeric antigen receptor (CAR) T cell therapy and synthetic lethality are essentially revolutionizing cancer therapy by improving immune responses and capitalizing on the specificity that is characteristic of cancer cells. However, off-target effects, tumor heterogeneity, and ethical dilemmas remain onerous challenges for clinical application. CRISPR delivery systems, despite playing a central role in advancing cancer therapies, also have prospects in optimizing the effectiveness of treatment against viral pathogens like BVDV. Advances in delivery systems using nanoparticles and viral vectors are mitigating against these challenges and improving efficacy and specificity of CRISPR reagent in vivo. In addition to this, continued progress in new technologies such as prime editing and base editing is predicted to improve precision and efficacy of CRISPR-based therapy. Since CRISPR technology is continuously developing, CRISPR's potential to treat both cancer and viral infections, like BVDV, simultaneously will be instrumental in precision medicine. This review highlights the revolutionary potential of CRISPR to revolutionize cancer treatment paradigms and brings hope for more effective and individualized therapy. With potential developments to emergent and potentiated CRISPR tools and reagents, it is predicted that they will play a center stage role in precision oncology and promote better patient results.